1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Crescent Biopharma agreed on July 14, 2026 to sell 8,094,793 ordinary shares and pre-funded warrants for 525,897 more shares in a public offering, with gross proceeds expected to be about $125.0 million. The company says the net proceeds, together with existing cash, should fund projected operating expenses, working capital and capital expenditures into the second half of 2028, but the sale adds shares outstanding for existing holders.
Ordinary shares priced at $14.50 each; pre-funded warrants priced at $14.499 each, for 525,897 shares in total
Expected net proceeds of about $115.9 million, or about $133.5 million if the underwriters' 30-day option for 1,293,103 additional shares is exercised in full
Offering expected to close on July 16, 2026, subject to customary closing conditions
Company estimates cash will fund operations into the second half of 2028
Prudential Financial disclosed preliminary second-quarter 2026 results before its August 4, 2026 earnings release, while its financial closing is not complete and actual results could differ materially. The company also reported that its annual actuarial assumption review will lead to one-time segment adjustments to adjusted operating income (AOI) in the quarter, with no material ongoing AOI impact expected.
PGIM assets under management were $1.49 trillion as of June 30, 2026, and PGIM other related revenues, net of related expenses, were approximately $60 million on an AOI basis for the quarter.
General Account alternative investment income for the quarter is estimated to be $20 million to $40 million below near-term expectations.
One-time AOI impacts: Retirement $(90) million; International Businesses $80 million; Group Insurance $30 million; Individual Life $30 million; U.S. Legacy Products $15 million, which sum to a net $65 million.
The earnings release and quarterly financial supplement are scheduled for August 4, 2026.
Winmark reported second-quarter net income of $10.4 million, or $2.81 per diluted share, for the quarter ended June 27, 2026, compared with $10.6 million, or $2.89 per diluted share, a year earlier. Total revenue rose to $22.0 million from $20.4 million, while selling, general and administrative expenses increased to $7.5 million from $6.6 million. The Board also approved a quarterly dividend of $1.02 per share, payable September 1, 2026.
Q2 total revenue was $21,966,000 versus $20,416,800 a year earlier; royalties were $20,117,000 versus $18,662,100.
Q2 diluted EPS was $2.81 versus $2.89; six-month diluted EPS was $5.31 versus $5.60.
Prior-year six-month results included $2.2 million of leasing income from the settlement of customer litigation.
Quarterly dividend of $1.02 per share: record date August 12, 2026; payment date September 1, 2026.
Progressive reported June 2026 results in a news release filed with the SEC. June net income fell to $779 million from $1,124 million a year earlier, and earnings per share fell to $1.34 from $1.91, while net premiums written rose 3% to $6,772 million. The combined ratio rose to 90.0 from 86.6, so underwriting profitability weakened in the month even as premium volume grew.
June net income was $779 million, down 31% from $1,124 million a year earlier.
June earnings per share were $1.34, compared with $1.91 a year earlier.
June net premiums written were $6,772 million, up 3%; the combined ratio was 90.0 versus 86.6.
Year-to-date net income was $6,129 million, up from $5,742 million for the same period in 2025.
Sprout Social said its board approved a workforce reduction of about 20%, or about 260 employees, on July 8, 2026, and began notifying affected employees on July 15. The company estimates pre-tax restructuring charges of $18.0 million to $20.0 million, mostly severance, with substantially all recognized in the third quarter of 2026. It also said preliminary results for the quarter ended June 30, 2026 are expected at the high end of its outlook ranges for revenue, non-GAAP operating income and non-GAAP net income per share, with full results due August 6, 2026.
Workforce reduction of about 20%, or about 260 employees, approved July 8, 2026; notifications began July 15, 2026
Estimated pre-tax restructuring charges of $18.0 million to $20.0 million, mainly cash severance and benefits, with substantially all recognized in Q3 2026
Preliminary Q2 2026 results expected at the high end of outlook ranges for revenue, non-GAAP operating income and non-GAAP EPS; full results due August 6, 2026 after market close
Conagra reported a fourth-quarter fiscal 2026 net loss of $1.6 billion, or $3.37 per diluted share, driven by $2.0 billion of non-cash goodwill and brand impairment charges, while adjusted EPS was $0.47. The board approved a quarterly dividend of $0.175 per share, an annualized rate of $0.70, and the company gave fiscal 2027 adjusted EPS guidance of $1.40 to $1.50, with new CEO John Brase citing margin restoration as a priority.
Q4 reported net sales rose 3.6% to $2.9 billion, but organic net sales were approximately flat
Full-year fiscal 2026 diluted loss was $4.00 per share; adjusted EPS was $1.72
Fiscal 2027 guidance: organic net sales down 3% to 1%, adjusted operating margin 10.0% to 10.5%, adjusted EPS $1.40 to $1.50
Quarterly dividend of $0.175 per share, payable September 2, 2026, to holders of record July 30, 2026
SemiLEDs disclosed that Nasdaq had notified it on January 30, 2026 that its stockholders' equity fell below the $2.5 million minimum, and that Nasdaq accepted its compliance plan with an extension of up to 180 calendar days. The company now believes it has regained compliance, based on stockholders' equity of $3.1 million as of May 31, 2026, but Nasdaq will keep monitoring and could start delisting if the next periodic report does not show compliance.
Nasdaq notice dated January 30, 2026 cited stockholders' equity below the $2.5 million minimum under Listing Rule 5550(b)(1)
Nasdaq accepted the company's plan and granted an extension of up to 180 calendar days from January 30, 2026
Total stockholders' equity was $3.1 million as of May 31, 2026, per the Form 10-Q
Company believes it has regained compliance; Nasdaq will monitor compliance in the next periodic report
Elevance Health reported second-quarter 2026 operating revenue of $49.8 billion, up 0.8% from a year earlier, while diluted earnings per share fell 13.1% to $6.71 from $7.72. The company raised its full-year 2026 diluted EPS guidance to at least $20.10 and its adjusted EPS guidance to at least $27.00, and said it is accelerating targeted investments. For shareholders, the higher outlook comes alongside lower quarterly profit and a higher benefit expense ratio.
Operating revenue was $49.8 billion in the second quarter of 2026, up from $49.4 billion a year earlier.
Diluted EPS was $6.71 versus $7.72 a year earlier; adjusted diluted EPS was $7.45 versus $8.84.
Full-year 2026 diluted EPS guidance was raised to at least $20.10 and adjusted diluted EPS guidance to at least $27.00.
Full-year 2026 operating cash flow guidance was raised to at least $6.0 billion; a $1.72 quarterly dividend is payable September 25, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.